Özet:

Comparison of anatomical and visual results of unilateral and bilateral intravitreal ranibizumab treatment in patients with diabetic macular edema. Material-Method: The files of patients with diabetic macular edema (DME) who underwent intravitreal ranibizumab (IVR) for a total of 3 times between April 2012 and May 2017 were reviewed retrospectively at Ataturk University Ophtalmology Department. Age, gender, duration of diabetes, duration between complaints and first ranibizumab treatment, other treatments, follow-up period, intraocular pressure, best corrected visual acuity (BCVA) were recorded. The paired-t test was used for statistical analysis, p<0.05 was considered significant. Results: 120 eyes of 80 patients with DME, whose 43 were males, 37 were females and 59-82 years old were included. 40 patients were treated unilaterally due to DME and 40 patients were treated bilaterally due to DME. Mean BCVA was 0.19±0.23 (Snellen) in unilateral cases, 0.21±1.35 in the right eye, 0.29±0.76 in the left eye in bilateral case on July 0.05) at the time of admission, in the 6thmonth, the average values were 0.42±0.32, 0.53±2.59, 0.49±1.92 (P0.05), respectively. Mean central foveolar thickness (CFT) was 458.1±177.6 μm in unilateral cases, 412.5±233.8 μm in right eye and 463.2±721.9 μm in left eye (June0,05) in bilateral cases. After treatment, at the 6th month, respectively; average CFT was 301.3±129.6 μm, 297.3±316 μm, 280.1±317.3 μm (June0.05). Conclusion: We didn't determine any significant change in CFT and BCVA in the other eyes of the patients applied unilateral IVR. When comparing unilateral IVR with bilateral IVR, we conclude that there is no statistically significant difference in terms of changes in BCVA and CFT and there is no synergistic effect of bilateral IVR administration.

Anahtar Kelimeler: